Patents by Inventor Siv Annegrethe Hjorth

Siv Annegrethe Hjorth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating autoimmune disease or chronic inflammation wtih antibodies that bind peptidoglycan recognition protein 1
    Patent number: 10906965
    Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 2, 2021
    Assignee: NOVO NORDISK A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Joseph Leon Kuijper, Xiaoting Tang, Mark Heipel, Siv Annegrethe Hjorth
  • ANTIBODIES THAT BIND PEPTIDOGLYCAN RECOGNITION PROTEIN 1
    Publication number: 20190119367
    Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
    Type: Application
    Filed: October 25, 2018
    Publication date: April 25, 2019
    Applicant: Novo Nordisk A/S
    Inventors: Vibeke Westphal STENNICKE, Christine Brender READ, Joseph Leon KUIJPER, Xiaoting TANG, Mark HEIPEL, Siv Annegrethe HJORTH
  • Antibodies that bind peptidoglycan recognition protein 1
    Patent number: 10150809
    Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: December 11, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Joseph Leon Kuijper, Xiaoting Tang, Mark Heipel, Siv Annegrethe Hjorth
  • ANTIBODIES THAT BIND PEPTIDOGLYCAN RECOGNITION PROTEIN 1
    Publication number: 20180016326
    Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
    Type: Application
    Filed: April 10, 2017
    Publication date: January 18, 2018
    Inventors: Vibeke Westphal STENNICKE, Christine Brender Read, Joseph Leon Kuijper, Xiaoting Tang, Mark Heipel, Siv Annegrethe Hjorth
  • Antibodies that bind peptidoglycan recognition protein 1
    Patent number: 9663568
    Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: May 30, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Joseph Leon Kuijper, Xiaoting Tang, Mark Heipel, Siv Annegrethe Hjorth
  • Antibodies That Bind Peptidoglycan Recognition Protein 1
    Publication number: 20150018528
    Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
    Type: Application
    Filed: November 30, 2012
    Publication date: January 15, 2015
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Joe Kuijper, Xiaoting Tang, Mark Heipel, Siv Annegrethe Hjorth
  • IL-21 variants
    Patent number: 8475784
    Abstract: IL-21 variants are provided wherein amino acids have been deleted in the region consisting of amino acid residues no. 65 to 98.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: July 2, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Siv Annegrethe Hjorth, Kent Bondensgaard, Dennis Madsen
  • IL-21 variant nucleic acids
    Patent number: 8383367
    Abstract: IL-21 variants nucleic acid sequences are provided that encode a peptide having deletions and zero to ten conservative amino acid substitutions in the region of amino acid residues 65-96 of SEQ ID. NO:2.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: February 26, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Siv Annegrethe Hjorth, Kent Bodensgaard, Dennis Madsen
  • Interleukin-21 variants with altered binding to the IL-21 receptor
    Patent number: 8211420
    Abstract: The invention is concerned with IL-21 polypeptide variants having an altered binding to the common gamma chain (c) of the IL-21 receptor and the use thereof in therapy.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: July 3, 2012
    Assignee: Novo Nordisk A/S
    Inventors: Kent Bondensgaard, Lishan Kang, Siv Annegrethe Hjorth, Dennis Madsen
  • INTERLEUKIN-21 VARIANTS HAVING ANTAGONISTIC BINDING TO THE IL-21 RECEPTOR
    Publication number: 20120107267
    Abstract: The invention relates to isolated IL-21 variant peptides having antagonistic binding to the common gamma chain (yC) of the IL-21 receptor, to pharmaceutical compositions comprising said peptides and to the use of said peptides in therapy.
    Type: Application
    Filed: March 10, 2010
    Publication date: May 3, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Lishan Kang, Kent Bondensgaard, Siv Annegrethe Hjorth
  • IL-21 VARIANTS
    Publication number: 20120082996
    Abstract: IL-21 variants nucleic acid sequences are provided that encode a peptide having deletions and zero to ten conservative amino acid substitutions in the region of amino acid residues 65-96 of SEQ ID. NO:2.
    Type: Application
    Filed: September 19, 2011
    Publication date: April 5, 2012
    Inventors: Siv Annegrethe Hjorth, Kent Bondensgaard, Dennis Madsen
  • IL-21 variants
    Patent number: 8034326
    Abstract: IL-21 variant are provided wherein amino acids have been deleted and/or substituted in the region consisting of amino acid No. 65-96.
    Type: Grant
    Filed: April 18, 2006
    Date of Patent: October 11, 2011
    Assignee: Novo Nordisk A/S
    Inventors: Siv Annegrethe Hjorth, Kent Bondensgaard, Dennis Madsen
  • INTERLEUKIN-21 VARIANTS WITH ALTERED BINDING TO THE IL-21 RECEPTOR
    Publication number: 20100196309
    Abstract: The invention is concerned with IL-21 polypeptide variants having an altered binding to the common gamma chain (c) of the IL-21 receptor and the use thereof in therapy.
    Type: Application
    Filed: December 20, 2007
    Publication date: August 5, 2010
    Inventors: Kent Bondensgaard, Lishan Kang, Siv Annegrethe Hjorth, Dennis Madsen
  • IL-21 VARIANTS
    Publication number: 20100143292
    Abstract: IL-21 variants are provided wherein amino acids have been deleted in the region consisting of amino acid residues no. 65 to 98.
    Type: Application
    Filed: October 26, 2007
    Publication date: June 10, 2010
    Inventors: Siv Annegrethe Hjorth, Kent Bodensgaard, Dennis Madsen
  • IL-21 Variants
    Publication number: 20090035254
    Abstract: IL-21 variant are provided wherein amino acids have been deleted and/or substituted in the region consisting of amino acid No. 65-96.
    Type: Application
    Filed: April 18, 2006
    Publication date: February 5, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Siv Annegrethe Hjorth, Kent Bodensgaard, Dennis Madsen